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Genotype imputation is potentially a zero-costmethod for bridging gaps in coverage and power between genotyping platforms. Here, we
quantify these gains in power and coverage by using 1,376 population controls that are from the 1958 British Birth Cohort and were
genotyped by theWellcome Trust Case-Control Consortiumwith the Illumina HumanHap 550 and Affymetrix SNPArray 5.0 platforms.
Approximately 50% of genotypes at single-nucleotide polymorphisms (SNPs) exclusively on the HumanHap 550 can be accurately
imputed from direct genotypes on the SNPArray 5.0 or Illumina HumanHap 300. This roughly halves differences in coverage and power
between the platforms. When the relative cost of currently available genome-wide SNP platforms is accounted for, and ﬁnances are
limited but sample size is not, the highest-powered strategy in European populations is to genotype a larger number of individuals
with the HumanHap 300 platform and carry out imputation. Platforms consisting of around 1 million SNPs offer poor cost efﬁciency
for SNP association in European populations.The advent of cost-effective, high-throughput genotyping
technologies has greatly aided the identiﬁcation of genetic
variants underlying human disease.1–4 Most genome-wide
association (GWA) studies use mass-produced genotype
chips designed to capture a given proportion of genetic
variation genome wide. The exact proportion of captured
variation differs among platforms and populations de-
pending on the number of single-nucleotide polymor-
phisms (SNPs) and their selection criteria.5 If sample size
is limited but ﬁnances are not, individuals should be gen-
otyped with the platform that provides the most genomic
coverage. When sample size is unlimited but ﬁnances are
restricted, a choice must be made between genotyping
the maximum number of individuals or the maximum
number of SNPs.
Imputation can potentially bridge the gap in coverage
between genome-wide SNP platforms. Here, direct geno-
type data are combined with population haplotype and
historical recombination information to predict an indi-
vidual’s genotype at ungenotyped SNPs. If all SNPs fea-
tured exclusively on a given chip can be accurately im-
puted on the basis of genotype data from a platform of
lower density (and cost), one should always choose to ge-
notype additional individuals in preference to additional
SNPs. In practice, not all of these SNPs are going to be
imputed accurately. Therefore, to ascertain whether the
number of SNPs or the number of individuals should be
maximized in the design of a GWA, two further questions
must be answered: (1) What proportion of SNPs found
exclusively on a dense GWA platform can be accurately
imputed from genotype data on less dense products? (2)
What effect in terms of coverage and power do these im-
puted SNPs have on genome-wide association analysis
and our choice of platform?112 The American Journal of Human Genetics 83, 112–119, July 20To answer these questions, we used empirical data from
the 1958 British Birth Cohort (58C)6 genotyped with both
the HumanHap 550 platform and SNP Array 5.0 by the
Wellcome Trust Case-Control Consortium (WTCCC).4
For a given platform, individuals with a genome-wide
genotype missingness > 5% were removed in addition to
related, duplicated, and individuals of non-European
descent identiﬁed during the original WTCCC project.4
Only the 1,376 individuals passing quality control (QC)
on both SNP Array 5.0 and HumanHap 550 platforms re-
mained under study. For both platforms, SNPs with a geno-
type call rate < 95%, or< 99% for SNPs with a minor-allele
frequency (MAF) < 5%, were removed in addition to SNPs
with a Hardy-Weinberg exact p value < 5.7 3 107. Of the
555,352 SNPs on the HumanHap 550 platform, 529,167
(95.3%) passed QC. Of the 500,568 SNPs on the SNP Array
5.0, 459,450 (91.7%) passed QC. Direct genotyping was
not carried out with the HumanHap 300 platform, so we
use the 313,504 SNPs (98.74% of all HumanHap 300
SNPs) that are also featured on the HumanHap 550 as
a proxy (HumanHap 300*).
We excluded 22,930 SNP Array 5.0 SNPs and 22,416
HumanHap 300 SNPs that were monomorphic in the CEU
HapMap panel. Some of these SNPs were polymorphic in
the 58C, and this highlights one disadvantage of basing
imputations on the small number of individuals in the
HapMap—variation at rare SNPs (MAF % 2%) that are
monomorphic in the HapMap will be lost (Figure 1). Phase
III of the HapMap project is currently ongoing and aims
at genotyping the ~1.7 million SNPs that are featured on
the HumanHap 1M or Affymetrix SNP Array 6.0. Approxi-
mately twice the number of samples currently in the
HapMapwill be genotyped. This improved resource should
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present study, imputations were based on CEU haplotype
information for all SNPs found in Phase II HapMap release
21 - NCBI Build 35 (dbSNP build 125) and data detailing
local recombination rates.7,8 These were combined with
direct genotyping data from either the SNP Array 5.0 or
HumanHap 300*. For each of these platforms, we imputed
all polymorphic HapMap SNPs (excluding those for which
we had direct genotype data), although only SNPs that are
featured exclusively on the HumanHap 550 were taken
forward for analysis. We could not use all HapMap SNPs
in our analysis because we only had direct genotypes avail-
able for comparison for those SNPs on the HumanHap 550
or SNP Array 5.0. Imputations were carried out with IM-
PUTE,9 which outputs the posterior probability that an
individual is each of three genotype classes (AA, AB, BB)
per SNP. For a given individual, any genotype with a poste-
rior probability R 0.9 was called, and genotypes at SNPs
with a maximum posterior probability below this thresh-
old were classiﬁed as missing. Typically, when analyzing
imputed genotype data, one should average over the distri-
bution of genotype probabilities and carry out a weighted
logistic regression analysis. However, here we wished to
directly compare the direct and imputed genotypes and
so created an ‘‘imputed genotype.’’ In total, we contrasted
imputed genotypes at 427,838 SNPs on the basis of the
SNP Array 5.0 and 203,859 SNPs on the basis of the
HumanHap 300* to direct genotypes from the lHumanHap
550 platform.
Before comparing the direct and imputed genotypes, we
removed SNPs that were likely to be imputed inaccurately.
These include SNPs that (1) have swapped strands between
Figure 1. Minor-Allele Frequency of
SNPs Directly Genotyped in 1,376 Sam-
ples from the 58C
(A) Minor-allele frequency for the 450,769
SNPs that are featured on the HumanHap
550 but not the Affymetrix SNP Array 5.0
and are also polymorphic in the 58C.
(B) Minor-allele frequency for the subset of
427,839 SNPs from (A) that are also poly-
morphic in the CEU HapMap data.
(C) Minor-allele frequency for the 215,998
that are featured on the HumanHap 550
but not the Illumina HumanHap 300* and
are also polymorphic in the 58C.
(D) Minor-allele frequency for the subset of
203,860 SNPs from (C) that are also poly-
morphic in the CEU HapMap data. Basing
imputations on haplotype data from the
HapMap causes variation at rare SNPs
(MAF % 0.02) to be lost.
HapMap release21 and release22; (2)
are removed from the latest versions
of genome-wide SNP chips; (3) have
more than 5% missing data in the
HapMap; (4) have more than 5% dis-
cordant genotypes between original HapMap genotyping
and the regenotyping of the CEU HapMap samples using
genome-wide SNP chips; and (5) show signiﬁcant differ-
ences in frequency when called with the BRLMM and
CHIAMOþþ4 genotype-calling algorithms. In total,
45,692 and 31,953 SNPs on the HumanHap 550 were re-
moved from the imputations based on SNP Array 5.0 and
HumanHap 300, respectively.
We applied partial least-squares projection to latent-
structures discriminant analysis (PLS-DA) to detect and
quantify systematic differences between direct and im-
puted genotypes. PLS-DA is a multivariate regression
method that relates a data matrix (X) to a singular (y) or
multiple (Y) response variables. In the current study, X is
a single matrix containing 1,3763 2 rows (each individual
is represented twice, once with a direct genotype vector
and once with an imputed genotype vector) and n col-
umns, where n is the number of SNPs under comparison.
Y is a vector classifying each individual genotype vector
(row) as either direct or imputed genotypes To get a numer-
ical estimate of how strongly a model based on the direct
and imputed genotypes can discriminate if a particular ge-
notype vector is from a direct or imputed source, we ap-
plied a cross-validation approach. Here, supervised models
are built with six-sevenths of the genotype vectors (both
direct and imputed). Each model is used to predict the or-
igin of the remaining one-seventh of genotype vectors. For
this ‘‘test set’’ of genotype vectors, the prediction model
uses only the genotypes to predict status (i.e., the known
status of the genotype vector is ignored). This procedure
is repeated seven times until the status of each genotypeThe American Journal of Human Genetics 83, 112–119, July 2008 113
Figure 2. Assessment of Imputed-Genotype Filtering Criteria
Assessment of filtering criteria for the Illumina HumanHap 550 genotypes based on Affymetrix SNP Array 5.0 (A–C) and Illumina Human-
Hap300* (D–F) genotype data.
(A and D) The number of SNPs passing filter thresholds based on per-SNP measures of mean maximum posterior probability (blue) or ge-
notype call rate (red). The number of these SNPs with an r2R 0.8 between direct and imputed genotype calls is shown after the removal of
SNPs not passing filtering thresholds based on per-SNP measures of mean maximum posterior probability (dark gray) and genotype call
rate (light gray).
(B and E) The PLS-DA Q2 value after the removal of SNPs not passing filtering thresholds based on per-SNP measures of mean maximum
posterior probability (blue) and genotype call rate (red). A Q2 value of 1 indicates that the current PLS model can perfectly predict whether
a given genotype vector is of direct or imputed origin. A Q2 of 0 indicates that the model has no power to predict the genotype’s origin.
(C and F) Mean r2 between direct and imputed genotypes after the removal of SNPs not passing filtering thresholds based on per-SNP
measures of mean maximum posterior probability (blue) and genotype call rate (red).vector has been predicted once. Subsequently, a cross-vali-
dation score (Q2) is calculated from the difference between
the observed and predicted genotype status values. Q2 re-
ﬂects the mean accuracy of the models for predicting the
status of the genotype vectors.10 Therefore, a Q2 of 1 indi-
cates that many systematic differences exist between direct
and imputed genotypes, and a Q2 of 0 indicates that no
such differences exist.
Filtering imputed data based on genotype call rate and/or
mean maximum posterior probability can remove many
poorly imputed genotypes. For both metrics, we incre-
mented the ﬁltering threshold from 0 to 1 in steps of 0.01
to ascertain which ﬁltering criterion most efﬁciently elimi-
nated differences between direct and imputed genotypes. A
PLS-DA model was ﬁtted to each data set, and Q2 was esti-
mated through cross-validation to assess the level of disper-
sion. For each ﬁltering criterion, the number of remaining114 The American Journal of Human Genetics 83, 112–119, July 200SNPs and themean r2 between the remaining direct and im-
puted genotypes were calculated. Filtering imputed SNPs
based on genotype call rate was more efﬁcient than mean
maximumposterior probability (Figure 2). Using SNPArray
5.0 genotypes,wewere able to accurately impute245,430of
the attempted 427,838 HumanHap 550 SNPs after remov-
ing all SNPs with an imputed genotype call rate % 0.89.
For imputations based on HumanHap 300* genotypes, we
were able to accurately impute 104,180 of the attempted
203,859 HumanHap 550 SNPs after removing all those
with a genotype call rate% 0.93. The applied ﬁltering crite-
ria represent the most efﬁcient means of removing system-
atic differences between direct and imputed genotypes in
our data. When we repeated the analysis by including the
SNPs that we believed, a priori, were likely to be imputed
badly, more stringent thresholds were required and fewer
SNPs were successfully imputed.8
Thecertainty thatan imputationalgorithmhas foragiven
imputedgenotypedoesnotalwaysperfectly reﬂect theaccu-
racy of imputation. Estimates of coverage and power would
be biased if we assumed all SNPs passing the imputed geno-
typecall-rateﬁlterswereaccurate, soonly thosewithan r2R
0.8 between known and imputed genotypes were taken for-
ward for further analysis (239,931and99,831SNPs imputed
from the SNP Array 5.0 and HumanHap 300, respectively).
Coverage was estimated with the formula outlined by Bar-
rett and Cardon,5 and results showed that approximately
half the difference in coverage between the SNP Array 5.0
or HumanHap 300 and the HumanHap 550 could be recov-
ered through imputation (Table 1).
We carried out simulations with the R statistical pack-
age11 to quantify the power to detect association with SNPs
present on the (1) SNP Array 5.0; (2) HumanHap 300; (3)
SNP Array 5.0 plus successful imputations; (4) HumanHap
300 plus successful imputations; (5) Affymetrix SNP-array-
6.0, and (6) Illumina HumanHap 1M. For each polymor-
phic CEUHapMap SNP (release 21), we calculated themax-
imum r2, in theCEUHapMapdata, between it and the SNPs
on each of the above genotyping platforms by using the
CEU HapMap data. For SNPs that are featured on the given
SNP chip,maximumr2 is therefore 1.We assessed thepower
of each SNP set to detect associations to SNPs of varying
allelic odds ratio (1.0–2.0, 0.01 increments) and risk-
increasing allele frequency (RAF) (0.05 % RAF < 0.10,
0.10%RAF<0.20, 0.20%RAF%0.50). Toobtain empirical
distributions of RAF and maximum r2, we selected at ran-
dom 10,000 HapMap SNPs within each of the RAF ranges.
If the causal variant is typed and n individuals are needed
to obtain a given power, then n/r2 individuals are needed
to obtain the same power if a tagSNP is typedwhere the cor-
relation between the causal SNP and the tagSNP is r2. There-
Table 1. Estimates of Genomic Coverage for Currently
Available Genome-wide SNP Platforms Alone and after
Imputation
Percentage of
Genomic Coverage
at r2 R 0.8
Percentage of
Genomic Coverage
at r2 ¼ 1
Affymetrix SNP Array 5.0 65 43
Affymetrix SNP Array 5.0
plus imputed SNPs
73 54
Affymetrix SNP Array 6.0 80 59
Illumina HumanHap 300 77 42
Illumina HumanHap 300
plus imputed SNPs
81 50
Illumina HumanHap 550 87 57
Illumina HumanHap 1M 91 68
Estimates evaluated with Phase II HapMap data from the CEU population.
Coverage estimates for Illumina HumanHap 1M and Affymetrix SNP-array-
6.0 are likely to be biased downward because the genotypes at approxi-
mately 10% of the SNPs on each platform are not currently publicly avail-
able for the CEU HapMap individuals. Where imputations are included, all
SNPs passing imputation-filter thresholds and with an r2 R 0.8 between
known and imputed genotypes are included along with the SNPs on the
genome-wide SNP chip.Thfore, for a given SNP, themaximum r2 can be used toweight
the sample size, and hence the power to detect an associa-
tion can be calculated for each of the SNP platforms under
study. Power was calculated with an assumed type I error
rate of 105 and a multiplicative disease model. For each
RAF range and allelic odds ratio, the mean power across
all 10,000 SNPs was calculated to provide an unbiasedmea-
sure of power (see Appendix 1).
Initially, ﬁxed baseline sample sizes of 1,000, 2,000, and
5,000 cases (and an equal number of controls) were simu-
lated across all platforms. The successfully imputed SNPs
signiﬁcantly improved the power of the SNP Array 5.0
and HumanHap 300 to detect association to rare SNPs
(0.05%MAF< 0.1) of reasonable effect (1.6 – 2.0), yielding
similar power as the SNP-array-6.0 and each other (Fig-
ure 3). For more common SNPs (or smaller effect sizes),
the differences between the platforms are less pronounced,
so the effect of imputation was reduced.
To reﬂect the cost efﬁciencies of the various platforms,we
carried out simulations where the baseline sample size for
a given platform was multiplied by the ratio in price per in-
dividual sample between that platform and theHumanHap
550 (sample-size ratios: SNP Array 5.0 ¼ 1.22; HumanHap
300¼ 1.32; HumanHap 550¼ 1; SNP-array-6.0¼ 0.99; Hu-
manHap1M¼0.57). Theseprice-per-sample ratioswere cal-
culated on the basis of indicative UK prices (including work
costs) communicated to us directly from Affymetrix and Il-
lumina and are includedhere as a guide only. Strikingly, un-
der all simulated scenarios, the HumanHap 300 with impu-
tation provides themost power (Figure 4). This is because it
is the cheapest of the GWA panels but provides, with suc-
cessful imputations, good genomic coverage (81%) of com-
mon variation (MAFR 0.05) at r2R 0.8 in populations of
European descent. Even without imputation, the Human-
Hap 300 platform appears to be the platform of choice if
sample size is unlimited but ﬁnances are not largely due
to a very competitive pricing. In terms of cost efﬁciency
for power to detect associations in samples of European de-
scent, the HumanHap 1M platform is of low value. How-
ever, ~10%of SNPs on this (and the SNP-array-6.0) platform
are not typed in HapMap samples and are not included in
our analyses. Furthermore, the HumanHap 1M has many
tagSNPs for African populations, which probably offer little
in terms of power and coverage in European populations.
Because of a lack of empirical genotype data, we are unable
to repeat our analyses for non-European populations.
Genome-wide SNP chips no longer focus solely on
capturing variation at SNPs in populations of European
descent and often include tagSNPs for other populations
or tags to capture copy-number variation (CNV). Indeed,
the HumanHap 550 has now been replaced by the Human-
Hap 610, which adds ~60,000 tags for CNVs. The implica-
tions of this on our work are minimal because the vast
majority of these CNV tags are not SNPs and therefore
have little effect on the coverage of, and power to detect
association to, variation in SNPs. However, as the features
on the various platforms become more varied, choosinge American Journal of Human Genetics 83, 112–119, July 2008 115
Figure 3. Mean power to Detect Association to a Disease with a Fixed Baseline Sample Size
Mean power to detect association (a ¼ 105) to a disease with a population prevalence of 0.0001 and a fixed baseline sample size across
different genome-wide platforms (simulated under varying risk allele frequency [RAF] and sample size).
RAF ranges are as follows: (A–C) 0.05% RAF < 0.10; (D–F) 0.10% RAF < 0.20; (G and H) 0.20% RAF% 0.50. Cases and controls are as
follows: (A, D, and G) 1,000 cases, 1,000 controls; (B, E, and F) 2,000 cases, 2,000 controls; (C, F, and I) 5,000 cases, 5,000 controls.
Mean power was calculated after 10,000 simulations where sample size per simulation for each SNP set was weighted by the maximum r2
between a randomly selected HapMap SNP (satisfying RAF constraints) and the SNPs on the given genotyping platform (with HapMap
release 21 CEU data).a platform for a particular study becomes more difﬁcult
and depends largely on the study population and the be-
lieved underlying genetics of the trait. For example if rare
CNVs are thought to play a role, then a GWA platform fea-
turing CNV tags or other complementary platforms should
be considered.12 If the sample consists of individuals of116 The American Journal of Human Genetics 83, 112–119, July 200non-European descent, then it is wise to obtain a platform
that covers variation in that population. If a platform that
does not have these added features is chosen, genotype im-
putation is unlikely to ‘‘recapture’’ this variation.
Without empirical genotyping data from other popula-
tions, it is difﬁcult to assess how transferable our results8
Figure 4. Mean Power to Detect Association to a Disease Where Baseline Sample Size Has Been Varied across Genome-wide SNP
Platforms to Reflect Relative Cost
Mean power to detect association (a ¼ 105) to a disease with a population prevalence of 0.0001 where baseline sample size has been
varied across genome-wide SNP platforms to reflect the genotyping cost per sample (sample-size ratios: SNP Array 5.0¼ 1.22; HumanHap
300 ¼ 1.32; HumanHap 550 ¼ 1; SNP Array 6.0 ¼ 0.99; HumanHap 1M ¼ 0.57).
RAF ranges are as follows: (A–C) 0.05% RAF < 0.10; (D–F) 0.10% RAF < 0.20; (G and H) 0.20% RAF% 0.50. Cases and controls are as
follows: (A, D, and G) 1,000 cases, 1,000 controls; (B, E, and F) 2,000 cases, 2,000 controls; (C, F, and I) 5000 cases, 5,000 controls.
Mean power was calculated after 10,000 simulations where sample size per simulation for each SNP set was weighted by the maximum r2
between a randomly selected HapMap SNP (satisfying RAF constraints) and the SNPs on the given genotyping platform (with HapMap
release 21 CEU data).are among populations. However, imputation quality is di-
rectly related to how well the haplotype map on which the
imputations were based documents variation within the
study population. If there is a good haplotype map for
the given population, we show that much power can beThgained through imputation. However, when a suitable
haplotype map is unavailable, it is unlikely that imputa-
tions will be of sufﬁcient quality to increase power signiﬁ-
cantly. Multidimensional scaling can be carried out to
compare individuals from a given study to individualse American Journal of Human Genetics 83, 112–119, July 2008 117
used to build a haplotype map, thus providing some indi-
cation of the suitability of that haplotype map for geno-
type imputation.
It seems likely that the majority of genotypes that can be
accurately imputed for a given data set are previously well
covered by the direct genotypes. Therefore, coverage is
only increased if the imputed SNPs capture variation at
SNPs not previously covered by the SNPs used to carry out
the imputation. The largest gains in coverage and power
stand to be made at those SNPs that are poorly covered by
the direct genotyping, although because of this fact they
are signiﬁcantly less likely to be imputed with sufﬁcient ac-
curacy to pass QC. However, even a small increase in maxi-
mum r2 between an untyped variant and a tagSNP can in-
creasepower toassociate thatparticular variantwithdisease.
A study evaluating the cost efﬁciency of GWA chips,
which did not address imputation, used the sample-size ra-
tio required to equate power as ameans of comparing GWA
platforms.13 The authors state when n ¼ 3,000, the Hu-
manHap 300 requires 1.34 times the number of individuals
as the HumanHap 550 for power to be equated. However,
given that under this scenario the power of the two plat-
forms is 0.929 and 0.957 respectively, there seems to be lit-
tle need to genotype extra individuals with the HumanHap
300. When power is high, power curves are reasonably ﬂat
and large sample-size increases are required for small
power gains. Therefore the sample-size ratio required to
equate power between platforms is a poor metric on which
to choose genotyping platforms because the ratio required
to gain practically equivalent power is often far less.
Price ratios used here are intended as a guide only. To en-
able power simulations to be carried out with study-speciﬁc
sample sizes and price ratios, we havemade the R code used
to carryout thepower simulations availableonline (seeWeb
Resources). This allows a thorough assessment of which
GWA platform is the most cost efﬁcient for a given study.
With producers of genome-wide SNP platforms continually
offering larger panels at increasing cost, it is a difﬁcult task
to accurately assess which platform offers the most value
formoney. Imputation cangreatly reduce interplatformdif-
ferences in coverage and power, and given current pricing
structures, can provide (in combination with direct geno-
type data) the most value for money in terms of genomic
coverage and power to detect association.
Appendix 1. Power Simulations
Power estimations for each SNP set were carried out under
the assumption of a multiplicative disease model. For
a given baseline sample size on the Illumina HumanHap
550 platform (550), the corresponding baseline sample
size for an alternative platform is given by n550 3 CR,
where CR is the cost ratio between the two platforms.
The genotype frequencies of the cases (affected by the
disease) and controls (unaffected by the disease) were sim-
ulated with the assumption of a disease population preva-118 The American Journal of Human Genetics 83, 112–119, July 200lence of 0.0001. The functional polymorphism was ran-
domly ascertained by selection of a random HapMap
SNP, i, from within a given RAF range (0.05 % RAF <
0.10, 0.10% RAF < 0.20, 0.20% RAF% 0.50).We assessed
power to detect association to this SNP at a¼ 105 by using
the above sample sizes and the Cochran-Armitage test for
trend. Effective sample size, En, which accounts for how
well SNP i is covered by the given genome-wide SNP
chip, was calculated for each platform and is given by
En ¼ n3max r2i ,
where n is the baseline sample size for the given platform
and max r2i gives the maximum r
2 between HapMap SNP
i and those on the given SNP set.
The genotype frequencies of the case and control co-
horts are as follows:
i 0 1 2
Case p0 p1 p2
Control q0 q1 q2,
where i denotes the number of high risk alleles. Genotype
frequencies at the SNP in unaffected individuals given the
RAF q are
q0 ¼ ð1 qÞ2,
q1 ¼ 2qð1 qÞ, and
q2 ¼ q2:
The disease probability (i.e., the probability that an indi-
vidual is affected given his or her genotype) is given by
4 ¼ k
l2q2 þ lq1 þ q0
,
where k is the disease population prevalence, l is the het-
erozygous genotype relative risk, andl2is hence the homo-
zygous genotype relative risk. Subsequently, the genotype
frequencies in affected individuals are
p0 ¼ 4ð1 qÞ
2
k
,
p1 ¼ 24lqð1 qÞ
k
, and
p2 ¼ 4l
2q2
k
:
Power is given by the c2 distribution with noncentrality
parameter (r) of
b1ðEn=2Þ2
b2 

b3
En

where
b1 ¼ ððq1  p1Þ þ 2ðq2  p2ÞÞ2,
b2 ¼ Enðp1þq1Þ2 þ 2Enðp2 þ q2Þ,
b3 ¼

Enðp1þq1Þ
2 þ 2Enðp2 þ q2Þ
2
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